Latest Articles

Publication Date
Hormonal Dysregulation and Neuroinflammation in Endometriosis: Convergent Druggable Pathways.

Endometriosis is a chronic, estrogen-dependent disorder defined by ectopic endometrial-like tissue growth, persistent inflammation, and aberrant innervation. Emerging evidence indicates that disease progression and symptom severity are driven by a …

Published: May 19, 2026, midnight
Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report.

Advanced maternal age (AMA) is a major challenge in reproductive medicine, compounded by coexisting conditions such as adenomyosis and endometriosis, which impair oocyte competence and endometrial receptivity. Prolonged gonadotropin-releasing hormone …

Published: May 19, 2026, midnight
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Yahoo

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Yahoo

Published: May 18, 2026, 4:44 p.m.
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Clinical Trials Arena

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Clinical Trials Arena

Published: May 18, 2026, 4:34 p.m.
Merck’s Sac-TMT met primary endpoints in endometrial cancer trial - TipRanks

Merck’s Sac-TMT met primary endpoints in endometrial cancer trial TipRanks

Published: May 18, 2026, 11:10 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Efficacy of different pretreatments in IVF outcomes in patients with endometriosis: A systematic review and network meta‑analysis.

To investigate the efficacy of different pretreatment protocols for women with endometriosis undergoing IVF. We systematically searched the Cochrane Library, PubMed, Medline, and Embase from inception to April 30, 2025, …

Published: May 18, 2026, midnight
Rates of Premature Ovarian Insufficiency and Surgical Menopause in Patients with Endometriosis.

Endometriosis is a chronic disorder that affects approximately 10% of reproductive aged women and can have wide-ranging detrimental effects. While endometriosis is known to be associated with early menopause, the …

Published: May 18, 2026, midnight
Common Gynecologic Issues in Patients Post-Kidney Transplantation.

Advances in kidney transplantation have transformed survival and quality of life for women with end-stage renal disease, necessitating a focus on long-term health care for this population. Female kidney transplant …

Published: May 15, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!